Table 3 Associated risk factors for non-response or loss-of-effectiveness in patients who received their first CGRP(R)-monoclonal antibody
Non-Responder (N = 23) | Loss-of-Efficacy (N = 13) | ||||||
|---|---|---|---|---|---|---|---|
OR | CI (95%) | Sig. | OR | CI (95%) | Sig. | ||
Female Sex | 0.582 | (0.13.-2.60) | 0.479 | 0.46 | (0.06–3.41) | 0.445 | |
Age | 0.98 | (0.93–1.02) | 0.267 | 0.94 | (0.88–1.01) | 0.051 | |
MMD | 1.09 | (1.01–1.17) | 0.028 | 1.41 | (1.25–1.60) | 0.496 | |
Psychiatric disorder | 2.90 | (0.38–8.53) | 0.055 | 6.05 | (0.99–36.81) | 0.051 | |
Medication overuse | 1.21 | (0.21–3.61) | 0.749 | 7.60 | (1.33–43.45) | 0.022 | |
Withdrawal | 0.88 | (2.27–5.16) | 0.853 | 0.70 | (0.23–8.67) | 0.406 | |
Number of prophylactic medications | 1.08 | (1.11–2.06) | 0.011 | 1.59 | (1.07–2.35) | 0.022 | |